About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
Qiagen will have an undisclosed number of layoffs as a result of the halted GeneReader development, though it plans to create new jobs elsewhere.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
Researchers from the TRACERx consortium analyzed blood and tumor samples to tease out features of lung cancers that are more likely to recur.
Researchers identified variants in the germline that appear to influence DNA methylation levels in prostate cancer tumors or in precancerous tissues.
Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.
UgenTec's FastFinder software platform uses artificial intelligence to enable analysis and interpretation of qPCR data, workflow automation, and genotyping.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
The firm will validate a model system for test development, integrate key test components, and compare Spotlight to other NIPT assays.
The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
Congenica has also integrated the Wellcome Sanger Institute's DECIPHER web-based genomic variant database into its clinical decision support product.
During the Black Death, Yersinia pestis isolates had low genetic diversity, but they diversified in multiple clades as the pandemic raged on.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
The in vitro diagnostic test can deliver molecular results from whole blood samples in less than three hours, the company said.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.